News | Nanologica

Exercise of Rights in Nanologica’s Stock Option Program

30 June, 2021

In Nanologica's stock option program 2018/21 exercise of rights in Nanologica’s stock option program has increased the number of shares in the company by 371,346 to 28,165,826 shares. As a result, the share capital increases to SEK 11,548,761. At Nanologica's Annual General Meeting on May 31, 2018, it was resolved to establish an incentive program of a maximum of 484,883 stock options for the company's employees. Each option entitles the holder to subscribe for one

Inlösen av optionsprogram i Nanologica AB

30 June, 2021

Nanologicas optionsprogram 2018/21 har lösts in av optionsinnehavarna, vilket medför en ökning av antalet aktier i bolaget med 371 346 till 28 165 826 aktier. Aktiekapitalet ökar som en följd av detta till 11 548 761 SEK. Vid Nanologicas årsstämma den 31 maj 2018 beslutades om att inrätta ett incitamentsprogram om maximalt 484 883 teckningsoptioner för bolagets anställda. Varje teckningsoption ger rätten att teckna en aktie i bolaget till en teckningskurs motsvarande 9,3 SEK under perioden 1

Nanologica’s patent granted in Australia

16 June, 2021

The Australian Patent Office has granted Nanologica’s patent titled ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. The patent protects the company’s technology platform NLAB Spiro® by giving exclusivity on methods for producing particles loaded with active pharmaceutical ingredients for lung delivery, among other dosage forms. ” This patent was granted in Europe last year and it is pleasing that we

Nanologicas patent godkänt i Australien

16 June, 2021

Den australiensiska patentmyndigheten har beviljat Nanologicas patent med titeln ”A process for manufacturing porous silica particles loaded with at least one bioactive compound adapted for lung, nasal, sublingual and/or pharyngeal delivery”. Patentet skyddar bolagets teknologiplattform NLAB Spiro® genom att ge ensamrätt på metoder för att tillverka partiklar som laddas med läkemedel för administrering genom bland annat inhalation. ”Det här patentet godkändes i Europa förra året och det är nu glädjande att vi utökar det geografiska

Nanologicas vd säljer aktier och köper optioner

8 June, 2021

Vd Andreas Bhagwani har privat och via sitt bolag Vega Bianca AB avyttrat 323 000 aktier i Nanologica AB av privatekonomiska skäl. Samtidigt löser han in 227 566 optioner till aktier. Efter transaktionerna uppgår Andreas Bhagwanis innehav i Nanologica AB till 2 019 764 aktier, motsvarande 7,3 procent av bolagets totala antal aktier, samt 165 000 optioner. ”Försäljningen görs av privatekonomiska skäl. Nanologica är fortsatt min största investering och mitt engagemang och min starka tilltro

Nanologica’s CEO sells shares and buys options

8 June, 2021

CEO Andreas Bhagwani has privately and through his company Vega Bianca AB divested 323,000 shares in Nanologica AB for private economic reasons. At the same time, he exercised 227,566 options to shares. Following the transactions, Andreas Bhagwani's holdings in Nanologica AB amounts to 2,019,764 shares, equivalent to 7.3 percent of the total number of shares in Nanologica, and 165,000 options. "The sale is made for personal economic reasons. Nanologica remains my largest investment and commitment,

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.